Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555893 · ClinicalTrials.gov registry record · NA
Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
A NA study, sponsored by Marshfield Clinic Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 194
- Enrollment target
NCT00555893 is a NA study that has completed, run by Marshfield Clinic Research Foundation. The registered enrollment target is 194 participants.
The verdict
NCT00555893, a NA study, has completed, sponsored by Marshfield Clinic Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 194 participants
- Enrollment target
Study Summary
This study is a randomized, blinded, placebo-controlled clinical efficacy trial to assess the duration and severity of influenza symptoms, and duration of viral shedding, in influenza patients receiving oseltamivir early and late relative to placebo. There are two main hypotheses in this study: 1. The duration of influenza symptoms, mean severity score, and duration of viral shedding are reduced in patients who initiate oseltamivir treatment late (48 to 119 hours) compared to those receiving no antiviral therapy. 2. Prior influenza vaccination (same season) reduces the duration of influenza symptoms and mean symptom severity in patients receiving oseltamivir after adjusting for age and timing of antiviral therapy (early versus late). There are two secondary hypotheses: 1. The duration of influenza symptoms, mean severity score, and duration of viral shedding are reduced in patients with influenza who initiate oseltamivir treatment early (\< 48 hours) versus late (48 to 119 hours). 2. The incidence of secondary complications is lower in patients initiating oseltamivir therapy late relative to those receiving no antiviral therapy.
Interventions
- DRUG Placebo
- DRUG Oseltamivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555893
The ClinicalTrials.gov registry entry for NCT00555893 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marshfield Clinic Research Foundation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00555893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555893 about?
NCT00555893 is a clinical study titled "Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza". This study is a randomized, blinded, placebo-controlled clinical efficacy trial to assess the duration and severity of influenza symptoms, and duration of viral shedding, in influenza patients receiving oseltamivir early and late relative to placebo. There are two main hypotheses in this study: 1....
What is the current status of trial NCT00555893?
This trial is currently completed. It is a NA study. The enrollment target is 194 participants. The study started on 2008-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00555893?
The interventions under investigation include: Placebo (DRUG), Oseltamivir (DRUG).
Who is sponsoring clinical trial NCT00555893?
This trial is sponsored by Marshfield Clinic Research Foundation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.